Verve Therapeutics (VERV) Competitors $4.23 -0.38 (-8.24%) Closing price 04:00 PM EasternExtended Trading$4.28 +0.04 (+1.06%) As of 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VERV vs. JANX, EVO, IMCR, MESO, ADPT, VERA, DYN, GPCR, ANIP, and SPRYShould you be buying Verve Therapeutics stock or one of its competitors? The main competitors of Verve Therapeutics include Janux Therapeutics (JANX), Evotec (EVO), Immunocore (IMCR), Mesoblast (MESO), Adaptive Biotechnologies (ADPT), Vera Therapeutics (VERA), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), ANI Pharmaceuticals (ANIP), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical products" industry. Verve Therapeutics vs. Janux Therapeutics Evotec Immunocore Mesoblast Adaptive Biotechnologies Vera Therapeutics Dyne Therapeutics Structure Therapeutics ANI Pharmaceuticals ARS Pharmaceuticals Janux Therapeutics (NASDAQ:JANX) and Verve Therapeutics (NASDAQ:VERV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations, profitability and community ranking. Is JANX or VERV more profitable? Janux Therapeutics has a net margin of -463.91% compared to Verve Therapeutics' net margin of -807.65%. Janux Therapeutics' return on equity of -10.47% beat Verve Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Janux Therapeutics-463.91% -10.47% -9.86% Verve Therapeutics -807.65%-35.23%-27.65% Does the media refer more to JANX or VERV? In the previous week, Verve Therapeutics had 2 more articles in the media than Janux Therapeutics. MarketBeat recorded 23 mentions for Verve Therapeutics and 21 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.44 beat Verve Therapeutics' score of 0.85 indicating that Janux Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 15 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verve Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in JANX or VERV? Janux Therapeutics received 11 more outperform votes than Verve Therapeutics when rated by MarketBeat users. Likewise, 70.97% of users gave Janux Therapeutics an outperform vote while only 61.11% of users gave Verve Therapeutics an outperform vote. CompanyUnderperformOutperformJanux TherapeuticsOutperform Votes4470.97% Underperform Votes1829.03% Verve TherapeuticsOutperform Votes3361.11% Underperform Votes2138.89% Which has preferable earnings & valuation, JANX or VERV? Janux Therapeutics has higher earnings, but lower revenue than Verve Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Verve Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJanux Therapeutics$9.34M160.99-$58.29M-$1.36-18.68Verve Therapeutics$59.61M6.89-$200.07M-$2.11-2.18 Do insiders & institutionals have more ownership in JANX or VERV? 75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 97.1% of Verve Therapeutics shares are owned by institutional investors. 29.4% of Janux Therapeutics shares are owned by insiders. Comparatively, 19.3% of Verve Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts recommend JANX or VERV? Janux Therapeutics presently has a consensus target price of $95.25, suggesting a potential upside of 275.00%. Verve Therapeutics has a consensus target price of $25.75, suggesting a potential upside of 458.57%. Given Verve Therapeutics' higher probable upside, analysts plainly believe Verve Therapeutics is more favorable than Janux Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Janux Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.09Verve Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, JANX or VERV? Janux Therapeutics has a beta of 3.24, suggesting that its stock price is 224% more volatile than the S&P 500. Comparatively, Verve Therapeutics has a beta of 1.82, suggesting that its stock price is 82% more volatile than the S&P 500. SummaryJanux Therapeutics beats Verve Therapeutics on 14 of the 19 factors compared between the two stocks. Get Verve Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VERV vs. The Competition Export to ExcelMetricVerve TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$389.56M$6.54B$5.43B$8.48BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-1.879.1426.7920.05Price / Sales6.89255.59395.67116.44Price / CashN/A65.8538.2534.62Price / Book0.636.546.864.61Net Income-$200.07M$143.51M$3.22B$248.19M7 Day Performance6.96%5.60%6.80%2.97%1 Month Performance-3.56%10.06%13.69%16.58%1 Year Performance-16.79%-0.86%18.25%8.16% Verve Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VERVVerve Therapeutics3.5437 of 5 stars$4.23-8.2%$25.75+508.7%-22.5%$377.08M$59.61M-1.72110Trending NewsEarnings ReportAnalyst RevisionGap UpJANXJanux Therapeutics2.7762 of 5 stars$26.06+2.0%$95.25+265.5%-47.1%$1.54B$10.59M-22.2730Positive NewsEVOEvotec1.4939 of 5 stars$4.17-3.0%$5.93+42.3%-21.9%$1.48B$788.22M0.004,200Gap DownIMCRImmunocore2.929 of 5 stars$29.54+4.0%$58.13+96.8%-39.1%$1.48B$310.20M-31.09320Positive NewsMESOMesoblast1.8344 of 5 stars$11.35+3.5%$18.00+58.6%+57.9%$1.45B$5.67M0.0080Gap DownADPTAdaptive Biotechnologies3.5631 of 5 stars$9.51+5.3%$9.83+3.4%+160.7%$1.44B$189.53M-8.72790News CoverageGap UpVERAVera Therapeutics3.3651 of 5 stars$22.49+3.6%$63.33+181.6%-48.2%$1.43BN/A-8.6240Positive NewsDYNDyne Therapeutics3.7712 of 5 stars$12.56+10.1%$46.85+273.0%-65.1%$1.43BN/A-3.53100Positive NewsGap DownHigh Trading VolumeGPCRStructure Therapeutics2.1255 of 5 stars$24.62-3.7%$78.00+216.8%-31.1%$1.41BN/A-33.27136Gap UpANIPANI Pharmaceuticals4.8288 of 5 stars$62.30-6.0%$80.13+28.6%-1.8%$1.36B$614.38M-113.27600High Trading VolumeSPRYARS Pharmaceuticals2.4345 of 5 stars$13.29-1.1%$31.00+133.3%+55.9%$1.31B$89.15M-26.0690Trending NewsEarnings ReportAnalyst Revision Related Companies and Tools Related Companies Janux Therapeutics Competitors Evotec Competitors Immunocore Competitors Mesoblast Competitors Adaptive Biotechnologies Competitors Vera Therapeutics Competitors Dyne Therapeutics Competitors Structure Therapeutics Competitors ANI Pharmaceuticals Competitors ARS Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VERV) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verve Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VERV Stock Free VERV Stock Alerts